Staff Directory

Last Updated



About Ciro Rinaldi

PROFESSIONAL EMPLOYMENT HISTORY: CURRENT POST: Jun 2010 -  Up to now UNITED LINCOLSHIRE HOSPITAL TRUST VISITING PROFESSOR IN BIOMEDICAL SCIENCE CONSULTANT HAEMATOLOGIST and CLINICAL DIRECTOR CLINICAL SUPPORT SERVICES JOINT DIRECTOR RESEARCH AND DEVELOPMENT EAST MIDLAND ECAG LEAD I am currently running 4 clinics: 2 general hematology clinic (Myeloma, Leukemia, LPD/CLL, MDS), 1 lymphoma clinic, 1 MPD clinic for an average number of 130 patients per week.  I am responsible for the Hematology Ward in Boston and Lincoln. I am participating in on call on a 1:4 based rota. Member of Leukemia, Myeloma, CLL, Lymphoma MDTs. Fully qualified for hematology lab activity (BM and PB reports, Transfusion issues etc.) I am responsible for teaching medical students and junior doctor. I am responsible for a molecular biology lab in Lincoln University. PREVIOUS EMPLOYMENTS: November 2007 – May 2010 Federico Ii University – Department Hematology Division , Biochemistry And Biotechnology CONSULTANT HAEMATOLOGIST AND ASSOCIATE RESEARCH PROFESSOR During work in the Haematology Division, I have independently diagnosed and treated about 300–350 annually of ill with blood diseases. In Federico II Haematology Department there are diagnosed and treated (annually 1500 – 1800)  patients with all blood diseases. The biggest groups are represented by patients with different kinds of anaemias (iron deficiency, megaloblastic anaemias,  haemolytic anaemias, aplastic and hypoplastic anaemias and sometimes secondary anaemias) and patients with malignant lymphomas (Hodgkin and non Hodgkin lymphomas, myeloma and related conditions). We often treated leukaemias (acute and chronic), myelodisplastic syndromes, myeloproliferative disorders,  and bleeding disorders (thrombocytopenic purpuras, drug-induced thrombocytopenias,  DIC), pancytopenias, agranulocytosis,  patients with haematological complications of chemiotherapy and even with hypersplenism due to non hematological reasons. I have been involved during the last 2 and half years in several National and International research and translational projects particularly in the field of chronic myeloproliferative neoplasia. I am actually an active member of several international and Italian working groups (American Society of Hematology, European Hematology Association, GIMEMA MPN working Package 9, Registro Italiano Trombocitemie, Societa’ Italiana di Ematologia e di Ematologia Sperimentale) and also a Principal Investigator in a study on JAK2 and secondary leukemia on behalf of the European Leukemia Net (ENL). Additionally I work in private practice for SDN Center in Naples (once a week) and I am a co-Investigator in a project named “GATA1 expression and its possible implication in Anagrelide activity” sponsorized by SHIRE. Concerning Lab work I analyzed preparations of peripheral blood smears (700-1000 annually), bone marrow smears (300 – 400 annually)  and preparation of cerebrospinal fluid under microscope. March 2006 – July 2007 University of Illinois at Chicago (UIC), Department of Medicine, Section Hematology/Oncology, Chicago IL, USA REASEACH SPECIALIST During this time I have been working in the field of MDS and MPN particularly in development of murine models. I studied the aggressive onco-protein EVI1 and its implications in the impairment of granulocytic and erythroid differentiation in murine and human MDS.  We have also generated by expressing the fusion gene AML1/MDS1/EVI1 [resulting from the t(3;21)] a mouse with a disease closely resembling human essential thrombocythemia.  At the end of this work I identified the overexpression of the transcription factor GATA1 in patients with essential thrombocythemia and polycytemia vera independently from the JAK2 V617F mutation suggesting its possible role as new molecular marker for these patients. 2003 - 2007 University Hospital Naples Italy RESIDENT IN HAEMATOLOGY CONGRESSES & CONFERENCES: 2006 - ASH (American Society of Hematology) Meeting 2007 - ASH Meeting - EHA (European Hematology Association) Meeting - SIE (Italian Society of Hematology) Meeting (Speaker) - SIES (Italian Society of Experimental Hematology) Meeting (Speaker) - Annapolis Hematology Workshop 2008 - ASH Meeting - EHA Meeting - ATENE workshop (Speaker) - SIES Discutiamone Insieme (Speaker) - SHIRE meeting (Speaker) - ENL Meeting (Speaker) 2009 - ASH Meeting - EHA Meeting - SIE Meeting (Speaker) - ENL Meeting (Speaker) - SIES Discutiamone Insieme (Speaker) - SHIRE advisory board (Speaker) 2010 - ENL Meeting (Speaker) TEACHING RESPONSIBILITIES: I have been involved in the last 6 years in training junior residents and medical students in clinical practice and medical theory. I also trained technicians, biologists and biotechnologists in laboratory practice and by formal classes in Naples (University Federico II) and in Chicago (University of Illinois at Chicago UIC).  I joined the University of Lincoln in 2011 as an Honorary Fellow (visiting Researcher) and I am one of the visiting lecturers for the Biomedical science/applied biomedical science module. I opened a molecular biology lab at the University of Lincoln where we are conducting studies focused on alternative pathways implicated in myeloproliferative disorders. RESEARCH AND PUBLICATIONS: 1. Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient. Addeo A, Rinaldi CR. Case Rep Oncol. 2013 May 30;6(2):285-8. 2. BRAF test and cytological diagnosis with a single fine needle cytology sample. Di Benedetto G, Fabozzi A, Rinaldi C, Rinaldi CR. Acta Cytol. 2013;57(4):337-40. 3. A case of abdominal sarcoidosis in a patient with acute myeloid leukemia. Baskaran V, Goodwin A, Athithan L, Addeo A, Rinaldi C. Case Rep Hematol. 2013;2013:379898. 4. A case of small cell carcinoma of the prostate and review of the literature. Addeo A, Rinaldi C, Panades M. Tumori. 2012 May;98(3):76e-8e 5. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Rinaldi CR, Rinaldi P, Alagia A, Gemei M, Esposito N, Formiggini F, Martinelli V, Senyuk V, Nucifora G, Pane F. Blood. 2010 Dec 23;116(26) 6. Intestinal amyloidosis: two cases with different patterns of clinical and imaging presentation. Mainenti PP, Segreto S, Mancini M, Rispo A, Cozzolino I, Masone S, Rinaldi CR, Nardone G, Salvatore M. World J Gastroenterol. 2010 May 28;16(20):2566-70. 7. JAK2V617F mutation persists in blasts and mature cells of transformed-JAK2V617F-positive-myeloproliferative neoplasia: A European Leukemia Net (ENL) study. Ciro R. Rinaldi, Paola Rinaldi, Marica Gemei, Francesco Grimaldi, Giorgia Battipaglia, Luigi Del Vecchio, Bruno Martino, Giorgina Specchia, Anna Candoni, Luigi Gugliotta, Alessandro M. Vannucchi, Tiziano Barbui, Fabrizio Pane. The American Journal of Hematology. Accepted Article Online: Feb 16 2010. 8. Acquired Hb H disease associated with elevated Hb F level in patient affected by primary myelofibrosis. Rinaldi CR, Rinaldi P, Pane F, Camera A, Rinaldi C. Ann Hematol. 2009 Dec 19. 9. EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. Cancer Res. 2009 Feb 15;69(4):1633-42. 10. Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia. Senyuk V, Rinaldi CR, Li D, Cattaneo F, Stojanovic A, Pane F, Du X, Mahmud N, Dickstein J, Nucifora G. Cancer Res. 2009 Jan 1;69(1):262-71 11. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F. Ann Hematol. 2009 Feb;88(2):151-8. Epub 2008 Aug 16. 12. Complete remission in a case of severe multi-resistant idiopathic thrombocytopenic purpura after Helicobacter pylori eradication. Rinaldi CR, Camera A, Viscardi G, Pane F, Rotoli B. Am J Hematol. 2008 Aug;83(8):683-4. 13. GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia. Rinaldi CR, Martinelli V, Rinaldi P, Ciancia R, del Vecchio L. Leuk Lymphoma. 2008 Jul;49(7):1416-9. 14. A methodology to study the deformability of red blood cells flowing in microcapillaries in vitro.Tomaiuolo G, Preziosi V, Simeone M, Guido S, Ciancia R, Martinelli V, Rinaldi CR, Rotoli B. Ann Ist Super Sanita. 2007;43(2):186-92 15. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. Cancer Res. 2007 Jun 15;67(12):5658-66. 16. RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function. Li D, Sinha KK, Hay MA, Rinaldi CR, Saunthararajah Y, Nucifora G. J Biol Chem. 2007 May 4;282(18):13542-51. 17. Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. Laricchia-Robbio L, Fazzina R, Li D, Rinaldi CR, Sinha KK, Chakraborty S, Nucifora G. Mol Cell Biol. 2006 Oct;26(20):7658-66. 18. Doppler echocardiography during the follow-up of hematological patients undergoing chemotherapy. Marra F, Galderisi M, Camera A, Rinaldi CR, Innelli P, Rotoli B, de Divitiis O. Int J Cardiol. 2007 Jan 18;114(3):403-4. 19. Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Camera A, Andretta C, Villa MR, Volpicelli M, Picardi M, Rossi M, Rinaldi CR, Della Cioppa P, Ciancia R, Selleri C, Rotoli B. Haematologica/Hematol J. 2003;4(5):346-50. 20. Regulation of normal and malignant megakaryopoiesis. Rinaldi CR, Boccuni PN and Nucifora G. Recent Progress in Cancer Research, 2007 – ISBN 81-7895-253-X –Charter 10– p173 REVIEW 21. Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia By Ciro Roberto Rinaldi, Ana Crisan and Paola Rinaldi Hematology - Science and Practice,  ISBN: 978-953-51-0174-1 Impact Factor: 60,276 PROFESSIONAL SOCIETY MEMBERSHIPS: 1. ITALIAN SOCIETY OF HEMATOLOGY (SIE) 2. ITALIAN SOCIETY OF EXPERIMENTAL HEMATOLOGY (SIES) 3. EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 4. AMERICAN SOCIETY OF HEMATOLOGY (ASH) 5. EUROPEAN LEUKEMIA NET (ENL) 6. ITALIAN ET REGISTRY (RIT) 7. MPN GIMEMA WORKING PARTY 8. NCRI MPN PERSONAL INTERESTS: I love play piano and sing. I can play tennis and soccer.

Department Responsibilities

Teaching. Lead of the MPN research Unit.

Subject Specialism

Philadelphia negative myeloproliferative disorders.


  • Medical Degree
  • PhD Biotechnology


  • Cellgene — Cellgene,
  • BCLF — BCLF,
  • Cellgene — Cellgene,
  • SHIRE — Shire,


Consultant Haematologist United Lincolnshire Hospital NHS Trust

Research Interests

  • Pathways in MDS.

  • Philadelphia negative myeloproliferative disorders. Alternative pathways implicated in MPN.

Research Projects

  • CD47/CALR EXPRESSION IN MYELOID NEOPLASM — awarded £90000 by Cellgene in 3
  • CD47/CALR EXPRESSION IN MPN AND MDS — awarded £50000 by Bclf in 3
  • GATA1 expression in MDS and its implication in azacitidine therapy — awarded £75000 by CELGENE in 3

Research in the Lincoln Repository

PhD Supervisor

3 PhD projects in my lab: 1) Role of JAK2 in MPN 2) Elucidating the role of CD47 and CALR in MPN and MDS 3) PU.1 and JDP2 in MDS I am happy to talk to and take on Uruguayan scholarship students.

Professional Affiliations